Our scientific publications in high-quality journals reflect the quality of the innovative research in Entasis’ laboratories.

Search by Program

Karlowsky JA, Hackel MA, McLeod SM, and Miller AA

In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021

Antimicrobial Agents and Chemotherapy (2022)

Shapiro AB, Moussa SH, McLeod SM, Durand-Reville T and Miller AA

Durlobactam, a new diazabicyclooctane β-lactamase inhibitor for the treatment of Acinetobacter infections in combination with sulbactam

Frontiers in Microbiology (2021)

O'Donnell J, Maloney K, Steidler M, Morrison R and Isaacs R

A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects

Clinical and Translational Science (2021)

Papp-Wallace KM, Shapiro AB, Becka SA, Zeiser ET, LiPuma JJ, Lane DJ, Panchal RG, Mueller JP, O'Donnell JP, and Miller AA

In vitro activity and in vivo efficacy of sulbactam-durlobactam against pathogenic Burkholderia species

Antimicrobial Agents and Chemotherapy (2021)

Lickliter JD, Lawrence K, O’Donnell J, and Isaacs R

Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a β-lactamase inhibitor, in healthy subjects

Antimicrobial Agents and Chemotherapy (2020)

Seifert H, Muller C, Stefanik D, Higgins PG, Miller A and Kresken M

In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy (2020)

Yang Q, Xu Y, Jia P, Zhu Y, Zhang J, Zhang G, Deng J, Hackel M, Bradford PA, and Reinhart H

In vitro activity of sulbactam/durlobactam against clinical isolates of Acinetobacter baumannii collected in China

Journal of Antimicrobial Chemotherapy (2020)

Sagan O, Yakubsevitch R, Yanev K, Fomkin R, Stone E, Hines D, O’Donnell J, Miller A, Isaacs R, and Srinivasan S

Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis

Antimicrobial Agents and Chemotherapy (2020)

McLeod SM, Moussa SH, Hackel MA, and Miller AA

In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally from 2016-2017

Antimicrobial Agents and Chemotherapy (2020)

O’Donnell J, Preston RA, Mamikonyan G, Stone E, and Isaacs R

Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects

Antimicrobial Agents and Chemotherapy (2019)